$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Medical drugs
Medical drugs
Medical drugs-Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
Is the combination of Inavolisib and Fulvestrant more effective?
2026-02-01 22:25:32
Check Details
Nilotinib (Nilotinib) domestic launch time and access methods
2026-02-01 22:25:32
Check Details
Recommended daily dosage and treatment regimen of Revumenib
2026-02-01 22:25:32
Check Details
Zenocutuzumab clinical trials show whether efficacy is stable
2026-02-01 22:25:32
Check Details
What are the adverse reactions of Cosibelimab?
2026-02-01 22:25:32
Check Details
What types of lung cancer patients does Ensartinib mainly treat?
2026-02-01 22:25:32
Check Details
What type of new anti-cancer drug does Datopotamab belong to?
2026-02-01 22:25:32
Check Details
Precautions during use of Mirdametinib
2026-02-01 22:25:32
Check Details
What are the contraindications that require special attention when using Vimseltinib?
2026-02-01 22:25:32
Check Details
How long does it take to take a complete course of Atrasentan?
2026-02-01 22:25:32
Check Details
Summary of real medication experience and feedback from patients with Telisotuzumab
2026-02-01 22:25:32
Check Details
How to deal with side effects of sunitinib
2026-02-01 22:25:32
Check Details
1
2
...
1855
1856
1857
1858
1859
1860
1861
...
2439
2440
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
AbbVie’s TEPKINLY (epcoritamab) Plus R² Granted EU Approval for Relapsed/Refractory Follicular Lymphoma
2
Global Oncology Update: Breakthroughs in Advanced Cancer Survival and Novel Therapies
3
Phase 1 Study Progress of Ceralasertib in Combination with Durvalumab for Advanced NSCLC and HNSCC
4
Global Breakthroughs in Cancer Drugs and Advanced Treatment Technologies
5
ROS and Cancer: The Potential of Natural Antioxidants
6
SKYSCRAPER-02C Study: New Hope for Extensive-Stage Small Cell Lung Cancer Treatment
7
LPCAT3: The Key Player in MASH Progression to Hepatocellular Carcinoma
8
Breztri Aerosphere Approved by US FDA for Maintenance Treatment of Asthma in Patients Aged 12 Years and Older
9
Datopotamab Deruxtecan as First-Line Treatment for Advanced Triple-Negative Breast Cancer: Full Interpretation of the Phase III TROPION-Breast02 Trial
10
Olaparib Plus Pembrolizumab Maintenance Therapy for Metastatic Pancreatic Cancer: Findings from the POLAR Phase II Basket Trial
11
From Causes to Treatments—Exploring Medical Breakthroughs
12
IRX4 Transcription Factor: New Research Insights on Colorectal Cancer Treatment Targets